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Abstract  
Context. Atypical femur fractures (AFFs) are serious adverse events associated with 
bisphosphonates and often show poor healing.  
Evidence acquisition. We performed a systematic review to evaluate effects of teriparatide, 
raloxifene and denosumab on healing and occurrence of AFF.  
Evidence synthesis. We retrieved 910 references and reviewed 67 papers, including 31 case 
reports, nine retrospective and three prospective studies on teriparatide. There were no 
randomized controlled trials. We pooled data on fracture union (n=98 AFFs on teriparatide) 
and found that radiological healing occurred within six months of teriparatide in 13 of 30 
conservatively managed incomplete AFFs (43%), nine of 10 incomplete AFFs with surgical 
intervention (90%) and 44 of 58 complete AFFs (75%). In nine of 30 non-operated 
incomplete AFFs (30%) no union was achieved after 12 months and four fractures (13%) 
became complete on teriparatide. Eight patients had new AFFs during or after teriparatide. 
AFF on denosumab was reported in 22 patients, including 11 patients treated for bone 
metastases and eight without bisphosphonate exposure. Denosumab after AFF was associated 
with recurrent incomplete AFFs in one patient and two cases of contralateral complete AFF. 
Eight patients had used raloxifene before AFF occurred, including one bisphosphonate-naïve 
patient.  
Conclusions. There is no evidence-based indication in patients with AFF for teriparatide apart 
from reducing the risk of typical fragility fractures, although observational data suggest that 
teriparatide might result in faster healing of surgically treated AFFs. Awaiting further 
evidence, we formulate recommendations for treatment after an AFF based on expert opinion. 
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Introduction 
Antiresorptive drugs such as bisphosphonates are widely used for the treatment of 
osteoporosis. Although effective for prevention of osteoporotic fractures, use of 
bisphosphonates is associated with rare but serious adverse events such as osteonecrosis of 
the jaw and atypical femur fractures (AFFs). An AFF is a spontaneous or low-trauma, 
subtrochanteric or femur shaft fracture often complicated by delayed or non-union (26%-
39%) and bilateral occurrence (2, 3).   
The age-adjusted incidence rate of AFF has been estimated to be 1.8 per 100,0000 person-
years in patients on bisphosphonate use under two years, increasing to 113 per 100,000 
person-years with over 8 years’ duration (4). It is thought that decreased bone resorption in 
bisphosphonate users results in suppressed bone turnover with accumulation of microcracks 
and homogeneously mineralized bone, making the bone more brittle and allowing the 
development of a spontaneous femur fracture. However, it is uncertain if bisphosphonates are 
causally related to AFF and incidentally AFFs do occur in bisphosphonate-naïve individuals 
(5).   Usually, bisphosphonates are discontinued after AFF is diagnosed. It has been shown 
that the risk of AFF decreases with 70% per year since the last use of antiresorptive drugs (6), 
although it is not certain that this risk reduction is also seen in patients who have already 
sustained an AFF.  
It is unclear if alternative osteoporosis drugs, particularly anabolic drugs, can promote AFF 
healing. Moreover, there is no guideline on how patients should be treated after an AFF where 
the risk of causing new atypical fractures should be weighed against the risk of fragility 
fractures when not treating osteoporosis. It has been proposed that teriparatide, an analog of 
parathyroid hormone (PTH 1-34) , is a safe option for treatment of osteoporosis in AFF 
patients, especially since it may also have a beneficial effect on the healing of AFF itself (7). 
Teriparatide is the only anabolic osteoporosis drug that is currently globally available. It 
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directly stimulates osteoblasts that might enable the formation of new, heterogeneously 
mineralized, bone at the fracture site of AFF. Besides teriparatide, antiresorptive drugs other 
than bisphosphonates, such as raloxifene and denosumab, may be considered for osteoporosis 
treatment in AFF patients. Denosumab is a human monoclonal antibody to RANKL and a 
potent inhibitor of bone resorption. Although AFFs have been reported in patients exposed to 
denosumab in case reports, it has not been clearly established in epidemiological studies how 
often denosumab, with or without preceding bisphosphonate use, is associated with AFF. The 
radiological healing or deterioration of AFF whilst on denosumab treatment is also not 
known. Raloxifene is a selective estrogen receptor modulator (SERM) that acts as an estrogen 
agonist in bone, with an antiresorptive effect that is milder than that of bisphosphonates and 
denosumab. The relationship between raloxifene and the occurrence of AFF has not been 
investigated. To our knowledge, this is the first review that explored denosumab and 
raloxifene in addition to teriparatide for medical management of osteoporosis in patients with 
AFF. Further, we investigated whether AFF occurs as an adverse event in clinical trials with 
two novel drugs for osteoporosis, romosozumab and abaloparatide. Romosozumab, an 
antibody to sclerostin with both anabolic and antiresorptive effects, was recently approved in 
Europe,  Japan and the U.S. for the treatment of (severe) osteoporosis. Abaloparatide is a 
synthetic analog of parathyroid hormone related protein. Strontium ranelate was not included 
in this review, since this drug is no longer available in most countries.   
We performed a systematic literature review to assess both the occurrence and the 
radiological healing of AFFs in patients who had used or were using teriparatide, denosumab 
or raloxifene. We formulate recommendations for healing of the AFF itself and for 
osteoporosis management in patients who have sustained an AFF and are at high risk of 
fragility fractures.    
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Methods 
We performed a search using key words related to atypical femur fractures and teriparatide, 
denosumab and/or raloxifene in Embase, Medline Epub (Ovid), Web of Science and 
Cochrane Central on 28th of May 2018. We separately searched for AFF as an adverse event 
in clinical trials with romosozumab or abaloparatide.  Reviews and articles written in a 
language other than English were excluded. Conference abstracts and original research 
articles were included. Articles were reviewed when AFF was diagnosed during or after the 
use of teriparatide, denosumab and raloxifene or when the radiological healing of AFF in a 
specified amount of time was reported using these drugs.  
A complete AFF was defined as a non-comminuted subtrochanteric or femur shaft fracture 
with a predominantly transverse fracture line that may become oblique as it progresses 
medially, after no or minimal trauma. An incomplete form of AFF was defined as a localized 
endosteal or periosteal thickening of the lateral cortex of the subtrochanteric femur with or 
without the presence of a lucent line. When the authors did not describe whether a fracture 
line was visible, we assessed medical imaging in the article to review the presence of a 
fracture line.  
We extracted data on sex, median age, ethnicity, use of bisphosphonates, surgical 
interventions and clinical or functional outcome after the AFF as far as this information was 
available.  
We assessed the occurrence of newly diagnosed AFF during or after the use of teriparatide, 
denosumab or raloxifene. Newly diagnosed AFF could either be the first clinical presentation 
of AFF, a second AFF of the contralateral femur, or recurrent AFF at the ipsilateral femur.  
For the assessment of radiological healing, the results were categorized for each type of drug 
according to study design (case report, retrospective cohort and prospective studies) and 
fracture type (complete AFF, incomplete AFF with or without surgical treatment) (Figure 1).  
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We assessed the total number of AFFs described in the literature with complete radiological 
healing at six months and 12 months after medical management. The number of 
conservatively treated incomplete AFFs that developed a lucent line or progressed to 
complete AFF was also noted. We pooled these data on healing from all article types to 
provide better insight into the effectiveness of the drugs for the healing of AFF.  
Radiological healing in complete AFFs and surgically treated incomplete AFFs was defined 
as adequate callus bridging. Radiological healing of an incomplete AFF on conservative 
management was defined by disappearance of a visible fracture line. Radiological healing of 
incomplete AFFs without a lucent line included flattening of cortical thi kening, 
disappearance of bone marrow edema on MRI-scan, or fading of hotspots on bone 
scintigraphy. Incomplete AFFs with localized cortical thickening only, without abnormalities 
on MRI-scan or bone scintigraphy were excluded from assessment of radiological healing, 
because focal cortical thickening can remain unchanged for  more than five years after 
diagnosis of incomplete AFF (8).  
We give our recommendations for teriparatide, denosumab and raloxifene in the medical 
treatment of patients with AFF. In order to address the decision-making in individual cases, 
we have formulated treatment advice for patients with a new diagnosis of AFF  and patients 
with AFF who have completed a two-year course of teriparatide. These considerations are 
based on the findings in this review and our expert opinion.  
 
Results: systematic review 
Our search retrieved 910 references. We selected two conference abstracts and 130 articles 
after screening of title and abstract. We replaced one conference abstract with the article that 
was published shortly after our search date (9, 10). After full-text reading, 67 articles were 
included for this review. Sections on teriparatide, denosumab and raloxifene have overlapping 
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references, because some case descriptions report on a combination of these treatments in 
AFF patients.   
 
Teriparatide 
We found 31 case reports, nine retrospective cohort studies and three prospective studies that 
have reported the effect of teriparatide on the radiological healing of AFF or occurrence of 
AFF. There were no published randomized controlled trials (RCTs). Detailed study 
descriptions of case reports, retrospective cohorts and prospective studies on teriparatide use 
in AFF patients can be found in Supplement 1(1). The demographic characteristics of the 
patients with AFF on teriparatide in case reports are stated in Table 1. Clinical variables and 
main findings from retrospective cohorts and prospective studies are summarized in Table 2 
and Table 3, respectively. The pooled data on radiological healing of AFF with teriparatide 
treatment are shown in Table 4.  
Teriparatide use and occurrence of AFF 
New AFF cases during or after teriparatide use were reported in eight patients and always 
occurred in patients with previous bisphosphonate exposure. The new AFFs occurred after 4, 
11, 18 and 24 months of teriparatide treatment in four patients (11-14).  The remaining four 
patients were described in a conference abstract which did not report the duration of 
teriparatide at time of diagnosis, but all developed new incomplete AFFs during teriparatide 
therapy in the same femur in which the first incomplete AFF was diagnosed (15).   
Six of the eight patients had been diagnosed with another AFF before, but in two patients the 
AFFs during teriparatide were the first AFFs (12, 13). One patient was diagnosed with a 
complete and contralateral incomplete AFF two years after stopping teriparatide without any 
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antiresorptive use in the meantime, but the patient had been treated for eight years with 
antiresorptives in the past (12).  
 
Teriparatide use after AFF  
Descriptive data of case reports, retrospective and prospective studies  
In 33 patients, a total of 24 incomplete AFFs and 27 complete AFFs were reported at the time 
of starting teriparatide treatment in 31 case reports. In 13 incomplete AFFs (54%) a fracture 
line was described or visible on the images in the publication, whilst the other cases of 
incomplete AFFs only showed focal cortical thickening on X-ray. The majority of cases were 
women (n=27, 82%). The mean age of all AFF patients was 67 years, ranging from 21 to 84 
years. Only a minority of studies (39%) reported ethnicity in 13 patients of whom nine were 
Caucasian. All cases of AFF were associated with the use of bisphosphonates. A total of 27 
patients (82%) were previously exposed to alendronate therapy. The mean treatment duration 
with antiresorptive drugs was 8.3 years, with a minimum duration of two years and a 
maximum exposure of 17 years. Three patients were diagnosed before the AFF with 
osteogenesis imperfecta (16-18) and one patient was genetically tested after the occurrence of 
bilateral incomplete AFFs which revealed hypophosphatasia (19).  
Nine retrospective cohorts that comprised a total of 201 AFF patients reported the effect of 
teriparatide use on radiological healing. Five cohorts involved incomplete forms only (15, 20-
23), three cohorts described complete fractures only (24-26) and one cohort was mixed (27). 
Six cohorts consisted of entirely Asian populations. In eight cohorts, all AFF cases were 
exposed to antiresorptive therapy and one cohort had 23% bisphosphonate-naïve patients. 
Three prospective studies comprised a total of 31 women and one man with a mean age of 73 
years who were treated for bisphosphonate-associated AFFs with teriparatide. Only one of 
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these studies had controls (n=9 patients) without teriparatide treatment (28). All three studies 
had a mix of complete and incomplete AFFs. Teriparatide was started immediately after 
surgery in one study and compared to delayed commencement of teriparatide six months 
postoperatively (29), whilst in the other two studies teriparatide was started between seven 
weeks to just over one year after the diagnosis of AFF (28, 30). The study by Greenspan et al. 
included four individuals with periprosthetic fractures (29), which strictly does not adhere to 
the diagnostic criteria for AFF as formulated by the American Society for Bone and Mineral 
Research (ASBMR) (3).  
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Radiological healing of AFF after teriparatide:  pooled data  
We pooled findings on fracture union and teriparatide use in case reports and retrospective 
studies. Apart from deterioration of incomplete AFFs to complete fractures in two patients 
(30),  no data on radiological healing from the three prospective studies could be used for this 
analysis, because either the fracture type (28) or time to healing (29, 30) could not be 
established from these publications.  
Data on fracture healing of  165 AFFs in 140 patients were pooled in Table 4, of which 96% 
were women (11, 14, 16-18, 21-27, 30-49). Teriparatide treatment was given for 98 AFFs 
(59%) while 67 AFFs from control groups in the cohort studies (all complete AFFs) did not 
receive teriparatide. The number of incomplete non-operated AFFs without teriparatide was 
too small for comparison (n=4) and there were no controls for surgically managed incomplete 
AFF. Healing of the fracture was achieved within six months of starting teriparatide in 13 
(43%) incomplete non-operated AFFs, nine (90%) surgically treated incomplete AFFs and 44 
(76%) complete AFFs. In the non-teriparatide treated group, 34 complete AFFs (51%) healed 
within six months. Complete AFFs appeared to heal faster with teriparatide compared to 
controls without teriparatide, but in both groups non-healing occurred at 12 months 
postoperatively in a small portion of patients: five AFFs (9%) in the teriparatide users; and 
four AFFs (6%) in those without teriparatide. Teriparatide was started in 11 patients because 
of signs of delayed healing or nonunion, ranging from two months to two years after the 
initial diagnosis of AFF (n=2 incomplete conservatively managed AFFs, n=9 complete AFFs) 
(14, 17, 18, 26, 31, 34, 36, 39, 41, 42, 44). Sixteen patients with 18 fractures had not 
discontinued bisphosphonates immediately after the diagnosis of AFF, ranging from three 
weeks up to one year, including four AFFs in four patients in the teriparatide-treated group 
(n=2 incomplete conservatively managed AFFs, n=2 complete AFFs) and 12 controls with 14 
complete AFFs (24, 25, 30, 31, 45).  Progression from incomplete to complete AFFs occurred 
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in four patients after initiation of teriparatide at varying intervals: nine days, two months, 
eight months, and 21 months (23, 30, 48).   
 
Denosumab 
Denosumab use and occurrence of AFF 
A total of 31 AFFs in 22 patients were reported after the use of denosumab in 14 case reports 
and two clinical trials.  The characteristics of these patients are summarized in Table 5. 
Ethnicity was stated only in three reports, with subjects of a Caucasian (n=1) or Japanese 
(n=4) background (50-52). Eleven patients with 15 AFFs were treated for osteoporosis with 
denosumab 60mg half-yearly (43, 52-60), while 16 AFFs in 11 patients have been reported 
after denosumab treatment with a high dose of 120mg monthly for metastatic bone disease 
(50, 51, 61-64).   
AFF occurred in eight patients without prior bisphosphonate use (9, 52, 59-61, 63, 64) of 
which four were in patients treated in an oncology setting (61, 63, 64), meaning that only four 
cases were documented of AFF after use of denosumab for management of osteoporosis (9, 
52, 59, 60).  
Two bisphosphonate-naïve individuals developed an AFF following the sixth and the 
fourteenth dose of denosumab in the FREEDOM-trial, a phase III clinical trial with 
denosumab in 4550 women with osteoporosis (59, 60). The first patient stopped denosumab 
and achieved fracture healing within six months, whilst the latter continued denosumab but no 
data on the healing of AFF are available in this case (personal communication by Amgen). 
One 60-year-old male who had been on glucocorticoids for asthma for over 30 years 
developed an AFF without any previous bisphosphonate use, two months after the second 
dose of denosumab that was given in a randomized controlled trial of denosumab in patients 
with glucocorticoid-induced osteoporosis (9). The fourth case without bisphosphonate-
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exposure concerns an incomplete, medially located AFF after only one injection of 
denosumab without abnormalities on X-ray but with  periosteal reaction on the MRI scan 
(52). Although stress fractures resembling AFF located on the medial instead of the lateral 
cortex have been described (65), this case does not meet the diagnostic criteria of AFF 
according to the ASBMR Task Force (3). The four bisphosphonate-naïve AFF cases treated 
for metastatic bone disease occurred after 21, 24 or 42 doses of 120 mg denosumab monthly 
(61, 63, 64).  
In two other cases, the influence of bisphosphonates on the risk of AFF cannot be excluded, 
but AFF was preceded by very short bisphosphonate treatment before starting denosumab (53, 
55). These two cases are very similar, since both patients had used alendronate for just a few 
weeks before switching to strontium ranelate because of side effects, which was subsequently 
replaced by denosumab, again because of intolerance to the drug. Both patients developed an 
AFF after three doses of denosumab (53, 55).  
These reports of AFF after denosumab  with minimal or no previous bisphosphonate use are 
suggestive of a role for denosumab in the development of AFF but the numbers are small and 
AFFs have also been reported rarely in patients never treated for osteoporosis (5, 66, 67). In 
another report, the AFF a peared to be triggered by one dose of denosumab in December 
2012, after five years of alendronate use between 1994-1999 (57) followed by a subsequent 
drug holiday for 13 years.  
 
Denosumab use after AFF  
We found seven papers that report on the use of denosumab after an AFF in 10 patients (18, 
45, 58, 68-71).   
Bisphosphonates switched to denosumab treatment 
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Seven patients switched from bisphosphonates to denosumab just before or after the first 
AFF. One patient with an incomplete AFF after four years of risedronate who underwent 
preventive placement of an intramedullary gamma-nail, was switched to denosumab and had 
delayed healing after six and 12 months (68).  
In a case series of complete AFFs associated with alendronate use (69), four patients started  
denosumab after the first AFF. There were four different outcomes. One patient had delayed 
fracture healing at 12 months but with minimal pain and almost the same activity level. One 
patient had a second complete AFF on the contralateral side one year after switching to 
denosumab; this contralateral AFF showed bridging callus formation at nine months’ follow-
up. One patient had bridging callus formation at 12 months and was pain-free. One patient 
had resumed normal daily activities at 18 months of follow-up and radiographs showed bone 
healing (69).  
In a case report one patient, who sustained a first complete AFF after one dose of denosumab 
and eight years of alendronate (58), continued  denosumab treatment but sustained a second 
complete AFF after three more doses of denosumab. The authors describe healing of both 
AFFs within five months postoperatively.  
Another case is described of denosumab started postoperatively for complete AFF with full 
weight-bearing after three months and no adverse events at 18 months of follow-up; complete 
bony union was achieved at one year postoperatively (70).  
Teriparatide switched to denosumab treatment 
Three cases are reported of denosumab therapy following teriparatide. One case involved 
bilateral incomplete AFFs without visible fracture lines after seven years of oral 
bisphosphonates who was treated with teriparatide for 18 months and a subsequent drug 
holiday of 12 months (71). The cortical thickening had almost completely flattened on X-rays 
when denosumab was prescribed as treatment for low bone mineral density (BMD). The 
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authors report that the patient had increasing thigh pain in both upper legs six months after the 
first dose of denosumab and that X-rays and bone scintigraphy showed recurrent incomplete 
bilateral AFFs with presence of a lucent line after which the surgeon decided to perform 
bilateral internal fixation (71). Two case reports (one with incomplete AFF and one with 
complete AFF) mention that the initiation of denosumab therapy had a good outcome in the 
short term (< one year) (18, 45) .   
Raloxifene 
Raloxifene use and occurrence of AFF 
Six papers (29, 49, 72-75) stated the use of raloxifene prior to the diagnosis of AFF in eight 
patients, although in four patients it was unclear whether this was preceded by bisphosphonate 
treatment (74, 75). Two patients had simultaneous use of raloxifene and bisphosphonates 
during six months and six years, respectively (49, 72). One had had prior bisphosphonate use 
(29). In a case series of surgically treated AFFs from Japan (73), a patient treated with 
raloxifene only was reported. This concerned a 77-year-old woman who had taken raloxifene 
and vitamin K2 for only one year when she sustained an AFF after a fall from standing height. 
Because delayed union was suspected, she received low-intensity pulsed ultrasonography 
three months postoperatively and partial fracture healing was seen nine months after the 
surgery (73).  
Raloxifene use after AFF 
We found reports of two patients treated with raloxifene after AFF, in both cases after 
teriparatide treatment (37, 46). One 63-year-old Asian woman received ten months of 
teriparatide after incomplete AFF with a visible fracture line, which was subsequently 
replaced by raloxifene. The fracture line had already diminished after three months of 
teriparatide and was invisible 15 months after the diagnosis, which was five months after 
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starting raloxifene (37). One 78-year-old woman with incomplete AFF with a lucent line 
received teriparatide; the fracture line had almost disappeared three months postoperatively. 
After 12 months of teriparatide, she switched to a SERM, most likely raloxifene, and had an 
event-free follow-up three years after the diagnosis (46).  
Romosozumab 
Twelve studies have been performed with romosozumab. Two studies reported three cases of 
AFF. One case of AFF occurred 3.5 months after the first monthly dose in a phase III clinical 
trial (76), but the association between romosozumab and the AFF is questionable given that 
the participant had complained of prodromal pain prior to the first romosozumab 
administration. Two cases of AFFs that occurred during open-label alendronate treatment 
after one year of monthly romosozumab in another trial (77).  
 
Abaloparatide 
A a total of nine clinical trials with abaloparatide were published. No cases of AFF were 
reported in patients who used or had used abaloparatide.  
Discussion  
In clinical practice there is great uncertainty of how to treat patients after they have sustained 
an AFF. This relates both to potential (positive or negative) effects of bone agents on the 
healing of the fracture and to the safety of osteoporosis drugs in those patients, who are still at 
high risk of fragility fracture after an AFF. Bisphosphonates are usually stopped, because 
patients are considered at risk of an AFF of the other femur since bilaterality is commonly 
reported, varying from 28% up to 44% (2, 7).    
In this systematic literature review, we aimed to assess the effects of teriparatide, denosumab, 
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raloxifene, romosozumab and abaloparatide on both the occurrence and healing of AFF in 
order to give recommendations for medical management. It is difficult to draw firm 
conclusions, because there are no reported RCTs of treatment in AFF patients with any of 
these drugs.  
Based on descriptions of 165 AFFs treated with teriparatide in observational studies, we made 
a crude estimate of effects of teriparatide on radiological healing of AFF after six and 12 
months. The majority of surgically treated incomplete (n=9, 90%) and complete AFFs (n=44, 
76%) healed within six months of teriparatide treatment, in contrast non-operated  incomplete 
fractures treated with teriparatide (n=13, 43%) and complete AFFs that were not treated with 
teriparatide (n=34, 51%). The reported data are insufficient for an evidence-based 
recommendation of the use of teriparatide to accelerate healing of AFF. Yet, keeping in mind 
the flawed study designs and heterogeneity between studies, the observational data might 
suggest that teriparatide could have a beneficial effect on the healing time of surgically treated 
AFF, although non-union after one year can still occur. There is no evidence of improved 
fracture healing for conservatively managed incomplete AFFs based on these observational 
data. Our findings clearly show that even during and after teriparatide treatment a new AFF 
can occur, either as a first presentation of AFF or as a second AFF of the contralateral femur, 
but only in patients previously treated with bisphosphonates.  
The role of teriparatide for healing of any type of fracture is debated. One meta-analysis of 
five RCTs in patients with osteoporotic fractures found a significantly shorter healing time in 
the teriparatide-treated group (78), whilst another analysis including also non-osteoporotic 
fractures did not demonstrate any effectiveness for teriparatide with regard to faster union 
(79). Two RCTs involved subjects with femoral fractures. In one trial with postmenopausal 
women and  low-trauma femoral neck fractures, teriparatide did not improve radiological 
fracture healing, but the sample size was too small to detect any differences (80). The other 
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RCT involved premenopausal women with acute stress fractures of the lower extremities and 
showed a tendency towards improved healing on MRI in the teriparatide group (83.3%) in 
comparison to controls (57.1%), but not statistically significant (p=0.18) (81).  
There are no documented cases of AFF with the use of abaloparatide. This drug might have 
equivalent effects on AFF as teriparatide given the biological similarity. The results from the 
literature search were insufficient to assess the effects on AFF healing by denosumab and 
raloxifene. Despite the lack of epidemiological studies, our analysis of the literature suggests 
that the absolute risk of AFF when using denosumab or raloxifene for osteoporosis is very 
low given the limited reports of AFF cases using these drugs, eleven and eight patients 
respectively, and they also mostly occurred after previous use of bisphosphonates. However, 
this risk may be increased in patients who have already had an AFF suggested by the reports 
of two patients with a second complete AFF (58, 69) on denosumab and in another patient 
with bilateral recurrent incomplete AFFs on denosumab even after use of teriparatide (71). 
These cases suggest curtailing use of denosumab treatment after an initial unilateral AFF. 
Romosozumab is linked to three AFF cases in clinical trials, but it remains to be seen if more 
cases of AFF will develop in patients treated with romosozumab with or without 
bisphosphonate exposure.  
Based on our findings we conclude that there is a clear need for randomized controlled 
clinical trials to evaluate whether teriparatide and/or abaloparatide enhances fracture union of 
(any type of) AFF, since this is the only drug that is not associated with the development of 
AFF without prior use of bisphosphonates. The observational studies in this review are biased 
and lack information on confounding factors such as time between diagnosis and starting 
medical treatment, surgical fixation techniques, smoking, body mass index, fracture 
localization, use of concomitant medication and postoperative weight-bearing protocols. 
Currently, one clinical trial is ongoing for patients with incomplete AFF who are randomized 
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to receive either placebo injections or teriparatide. Changes in pain score and physical 
function using the WOMAC scale and the proportion of participants requiring surgery after 
12 months serve as primary outcomes (82). There are no trials registered investigating 
teriparatide for complete AFF, non-healing AFF or electively operated incomplete AFF. Also 
no trials are currently evaluating the risks and benefits of antiresorptive therapy compared 
with placebo in AFF patients after stopping teriparatide or in AFF patients managed 
conservatively or surgically. It is difficult to set up an adequately powered study because of 
the low incidence of AFF. Therefore, an international registry of AFF cases could be very 
useful to gain insight into the safety and efficacy of osteoporosis drugs in relation to fracture 
healing, bone mineral density and bone turnover and development of new AFFs in these 
patients, but this is only possible when AFF patients are referred to specialized centers.  
 
Recommendations for clinical practice based on expert opinion 
Based on the results in this review and our expert opinion we advise on medical treatment for 
patients with AFF. Our recommendations for medical treatment are summarized in a decision 
tree (Figure 2), encompassing the occurrence of AFF when using bisphosphonates or 
denosumab and what to do after a patient with AFF has completed a two-year course of 
teriparatide. In any case, extensive monitoring with imaging of both upper legs is advised 
during the first one or two years after the diagnosis of AFF, because non-healing of AFF and 
contralateral AFF may still occur, even on teriparatide.  
When AFF is diagnosed during the use of bisphosphonates or denosumab, it is recommended 
to stop this treatment, since continuation may lead to worsening of the AFF or a new 
contralateral AFF. To prevent a rebound effect, discontinuation of denosumab could be 
followed by a short course of bisphosphonates or SERMs in patients with surgically treated 
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AFFs. In patients at low fracture risk without prevalent vertebral fractures who have only had 
one or two half-yearly injections, consider stopping denosumab treatment without subsequent 
therapy. After healing of bilateral, surgically managed AFFs, bisphosphonates or denosumab 
may be continued. It should be kept in mind that discontinuation after three or more years of 
bisphosphonate treatment may result in increased risk of hip fractures and clinical vertebral 
fractures as shown by some studies (83, 84), although this was not found in another recent 
retrospective analysis of a population-based cohort (85). Continuation of bisphosphonates 
might lead to a risk of atypical fractures at skeletal sites other than the femur. Anecdotally, 
spontaneous fractures of  other long bones e.g. ulna, forearm and tibia have been reported in 
relation to bisphosphonate use (86-93), but no association has been established and the 
potential risk of such atypical fractures does not appear to weigh against the risk of typical 
osteoporotic fractures.  
Teriparatide might be started for surgically treated AFFs, although strong evidence for 
improved fracture union is lacking. Further, teriparatide, SERMs, romosozumab or 
abaloparatide may alternatively be considered in patients at high risk of fragility fractures. 
SERMs are preferably prescribed in relatively young postmenopausal women who are at low 
risk of hip fractures and deep vein thrombosis (94). Hormone replacement therapy or tibolone 
might be considered when SERMs are not tolerated, preferably in younger women (< 65 
years) who do not have an increased risk of venous thromboembolism, without a history of 
myocardial infarction or stroke and also keeping in mind the increased breast cancer risk (94). 
If the patient is not eligible for any of the aforementioned drugs, calcitonin can be prescribed 
as in accordance with the recent guideline of the Endocrine Society on pharmacological 
management of osteoporosis (94). The definition of high risk of fragility fractures varies 
across countries, but is often defined by a hip BMD T-score ≤ -2.5 SD, older age (70-75 
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years), a recent fragility fracture, other strong risk factors for fracture or a FRAX fracture risk 
score that is above country specific thresholds (95).  
  
After two years of teriparatide, subsequent therapy may be given with raloxifene (or hormone 
replacement therapy) in women and – in those with bilateral surgical fixation of AFF – 
denosumab or bisphosphonates. In patients at the end of a (short) course of teriparatide who 
have low bone turnover markers after teriparatide or who are deemed to be at low risk of 
osteoporotic fractures teriparatide may be discontinued without further antiresorptive 
treatment, but close monitoring of BMD and bone turnover markers is recommended.  
The considerations for each individual drug are given in more detail below. 
 
Teriparatide 
There is no evidence-based indication for teriparatide to enhance healing of AFF, but a 
tendency towards faster healing with teriparatide for surgically managed AFFs is seen in the 
limited, observational data. Hence teriparatide 20ug daily, when reimbursed, might be 
considered for surgically-treated AFF, both incomplete AFF and complete AFF. Even during 
the use of teriparatide, non-unions do still occur in surgically managed AFF.  The limited data 
on conservatively managed incomplete forms of AFF and use of teriparatide, do not 
demonstrate improved fracture healing, but should be interpreted with caution, pending the 
result of an RCT that is awaiting results. When teriparatide is given for the sole purpose to 
enhance fracture healing of AFF, a short treatment duration of three to six months may 
suffice.   
Teriparatide is a reasonable treatment option for patients who have had an AFF and are still at 
high risk for fragility fractures. A big clinical dilemma is what to do after a full two-year 
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course of teriparatide treatment. Normally, antiresorptive therapy is advised after two years of 
teriparatide, because the positive effects on bone mass and strength will in time disappear, as 
with any drug without skeletal retention. Some patients with AFF may have inherent low 
bone turnover, for example due to an underlying monogenetic disease (96) or due to previous 
long-term use of bisphosphonates. It can be speculated that accelerated bone loss after 
cessation of teriparatide may not occur in these cases. A few studies describe the effect of 
teriparatide on bone turnover in AFF patients, but the results are inconclusive. Administration 
of teriparatide during six months has been associated with a significant increase in bone 
turnover markers in patients with AFF (28, 30) and values returned almost to baseline level 
after two years of teriparatide (30), but pre-treatment values varied widely (30, 97) and bone 
turnover markers did not correlate with histomorphometric findings from bone biopsies 
before and after teriparatide treatment in AFF patients (97).  
We suggest monitoring bone turnover markers on a regular basis in patients with AFF before, 
during and after teriparatide treatment and considering antiresorptive drugs when levels start 
to increase or when BMD starts to decrease in patients at high risk of fractures. In this 
situation, we suggest either a SERM, romosozumab, calcitonin, tibolone, estrogens, 
denosumab or bisphosphonates, based on sex and on bilaterality of surgical intervention (see 
below).   
Denosumab 
When a patient sustains an AFF during the use of denosumab, the risk of a rebound effect 
with rapid loss of BMD and potential risk of multiple vertebral fractures following cessation 
of denosumab (98) must be weighed against the potentially increased risk of a contralateral 
AFF when continuing denosumab. Patients who have already had vertebral fractures appear to 
be at greatest risk of developing multiple vertebral fractures after denosumab discontinuation.  
In general, a course of bisphosphonates is recommended after stopping denosumab (98). This 
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is not advisable for a conservatively managed incomplete AFF, but a short course of a SERM 
or bisphosphonates may be considered in patients with bilateral surgically treated AFFs or a 
unilateral surgically treated AFF without any radiological signs of incomplete AFF of the 
contralateral femur. Denosumab could be stopped without follow-up therapy in patients at 
low risk of fragility fractures without prevalent vertebral fractures, especially in those who 
have only had one or two half-yearly injections of 60 mg subcutaneously.  
For patients at high risk of fragility fractures, a switch to teriparatide or a SERM could be 
considered. However, the rebound effect after stopping denosumab might still occur since 
teriparatide increases bone turnover. One should also be aware of a decrease in BMD 
especially at cortical sites, as was seen in osteoporotic women who transitioned to teriparatide 
after two years of denosumab in the DATA-switch study (99). Alternatively, hormone 
replacement therapy or tibolone can be considered in women in absence of contra-indications 
such as a high risk of breast cancer of deep veen thrombosis, history of stroke or myocardial 
infarction. Calcitonin is an option if the patient does not tolerate any of the aforementioned 
drugs (94).  
Denosumab could be continued or initiated when the patient has bilateral surgically treated 
AFFs and a persistently high risk of fragility fractures, including those who have completed 
two years of teriparatide. Denosumab therapy for up to 10 years has been associated with 
increasing BMD and low fracture incidence (59). Long-term use of denosumab could 
especially be considered in elderly patients with a life expectancy of less than 10 years, for 
whom this may serve as life-long osteoporosis treatment.  
Raloxifene 
Raloxifene could be considered as follow-up therapy after teriparatide when bone turnover 
markers are high in postmenopausal women who do not have a history of venous thrombo-
embolic events. Preferably it is given to women who are relatively young and are at lower risk 
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of hip fractures. As mentioned above, it could also be considered in patients who have to stop 
denosumab because they are at risk of another AFF and to potentially prevent the rebound in 
bone turnover and risk of multiple vertebral fractures, especially when they have already had 
vertebral fractures. However, no studies have been performed using SERMs to prevent 
rebound after stopping denosumab. Because it has a weaker antiresorptive effect than 
bisphosphonates or denosumab and few cases of AFF have been reported on raloxifene, this 
may be a preferred option after teriparatide (100, 101). Yet it should be kept in mind that 
raloxifene is not regularly prescribed for osteoporosis, hence a low number of AFF associated 
with raloxifene does not guarantee a lower risk of AFF compared to other antiresorptive 
drugs.  
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Legends 
Figure 1. The results for each type of drug were categorized according to study design 
and fracture type.   
 
Figure 2. Decision tree with considerations for medical management after AFF.   
^ Definition may vary across countries, e.g. a hip BMD T-score ≤ -2.5 SD, older age (70-75 
years), a recent fragility fracture, other strong risk factors for fracture or a FRAX fracture 
risk score that is above country specific thresholds (95).  
*Raloxifene or bazedoxifene are preferably prescribed in relatively young postmenopausal 
women who are at low risk of hip fractures and deep vein thrombosis (94), or in women in 
whom the use of teriparatide is contra-indicated. 
#In case of intolerance to SERMs, hormone replacement therapy or tibolone could be 
considered in women with a low risk of deep vein thrombosis and breast cancer, without a 
history of myocardial infarction or stroke (94).  
+ Switching denosumab to teriparatide may result in progressive BMD loss.  
0 Be aware that antiresorptive therapy may be needed after stopping denosumab.  
A Calcitonin can be prescribed in patients who are not eligible for bisphosphonates, SERMs, 
hormone replacement therapy, tibolone, abaloparatide or teriparatide.  
 
Table 1. Demographic characteristics of case reports on teriparatide use in AFF 
patients. 
NS = not stated, F = female, M = male 
1 From case series, only patients in whom the effect of teriparatide could be assessed on 
healing or occurrence of AFFs were included in this table.  
2The number of AFFs included (contralateral) AFFs that had already healed by the time 
teriparatide was started. This means that the total number of AFFs in this table is higher than 
the total number of AFFs that was treated with teriparatide.   
3 The country of the affiliation is given, when ethnicity of the AFF case was not specified in 
the article.   
4 The types of bisphosphonates prior to the occurrence of the first AFF. When a patient had 
used several antiresorptive drugs, the total number of years the patient had used this specific 
drug is indicated in brackets. In some cases, type of bisphosphonates was unknown 
(“bisphosphonates”). For intravenous bisphosphonates the dosage and treatment interval are 
given in the table. Alendronate dosages included 70mg weekly or 10mg daily. Etidronate was 
given 400mg two-weekly, ibandronate 150mg monthly, risedronate 35mg weekly and 
raloxifene 60mg daily.  
5 The total duration of antiresorptive drugs use prior to the first diagnosis of AFF is given in 
years, not including drug holidays.  
6 No access to full-text article. 
 
Table 2. Summary of retrospective cohorts of AFF patients and use of teriparatide.  
TPT = teriparatide, AR = antiresorptive, NS = not stated. 
Percentage of women, mean age, antiresorptive use and mean duration of antiresorptive 
treatment were based on the whole cohort, including controls.  
*When the number of AFFs is not stated in the article, the number of patients is given.  
 
Table 3. Summary of prospective studies on AFF patients and use of teriparatide. 
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TPT = teriparatide, AR = antiresorptive, NS = not stated 
Percentage of women, mean age, antiresorptive use and mean duration of antiresorptive 
treatment were based on the whole cohort, including controls.  
* The number of patients is given.  
 
Table 4. Radiological healing of AFF after teriparatide: pooled data.  
NA = not applicable, TPT = teriparatide  
Five AFFs that underwent surgical procedures from Takakubo et al. were categorized as 
complete fractures. In the study by Miyakoshi et al., one non-operated incomplete AFF and 
one surgically treated incomplete AFF on teriparatide and eight complete AFFs without 
teriparatide were labeled as healed by the authors between six and 24 months. These 
fractures were categorized as “healing at 12 months”. From the study by Sato et al., only 
progression to complete AFF in one patient on teriparatide and one without teriparatide 
could be established, whilst for the other 19 incomplete AFFs the fracture healing was not 
specified. 
Included articles:(10, 13, 15-17, 20-26, 29-38, 40-49)  
Excluded: Patients (n=7) without fracture consolidation after ≤ six months of teriparatide use 
(18, 50, 51) (n=3), (20) (n=3 with surgery after three months), (48) (n=1, case no. 3), 
fracture healing could not be assessed with certainty (52, 53), duration of fracture healing or 
fracture type were not reported (14, 19, 27, 28).  
 
Table 5. Occurrence of AFF during or after the use of denosumab.   
BP = bisphosphonate. Parameters are based on the time of the first AFF. Mean duration of 
bisphosphonates was calculated in bisphosphonate-users only. Incomplete fractures with 
progression to complete fractures were excluded from the number of incomplete AFFs. 
Denosumab was dosed 120mg monthly in oncological patients and 60mg six-monthly in 
osteoporosis patients. Missing data: age (n=2)(63), mean duration of bisphosphonates (n=3) 
(55), median no. of denosumab doses (n=3) (55). Included articles: (8, 42, 54-68)  
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Figure 1.  
  
Drug
Teriparatide
Denosumab
Raloxifene
Design
Case report
Retrospective 
cohort
Prospective 
study
Fracture type
Complete AFF
Incomplete AFF 
(conservative)
Incomplete AFF 
(surgical)
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Low risk of 
fragility fractures 
 Diagnosis of AFF  
High risk of 
fragility 
fractures^ 
Figure 2.   
 Risk estimation for fragility 
fractures 
 Stop BPs or DMAB 
 Monitor healing and/or 
development of new AFF with 
imaging of both upper legs 
during 1 to 2 years  
Unilateral or nonoperated AFF(s): 
 1. TPT or APT for 2 years+ 
 2. If 1 is not an option, consider: 
 RMAB 
 SERM* 
 HRT or tibolone# 
 CalcitoninA 
Bilateral surgically managed AFFs: 
1.  TPT or APT for 2 years+ 
2. If 1 is not an option, consider: 
 Restart DMAB 0 or BPs  
 RMAB 
 SERM * 
 HRT or tibolone# 
 CalcitoninA 
  
Nonoperated AFF(s) 
 Currently no evidence for faster 
AFF healing with TPT  
 If ≥2 DMAB injections,  give a short 
course of BPs or SERM * 
 
Surgically managed AFF 
 No hard evidence, but weak data 
might support faster healing with 
TPT+ and might be considered for 3-
6 months depending on availability 
 If ≥2 DMAB injections,  consider a 
short course of BPs or SERM*  
 
After TPT, consider these options:  
 BPs or DMAB0 if bilateral intramedullary pins 
 SERM* 
 RMAB 
 HRT or tibolone# 
 CalcitoninA 
 If evidence for very low bone turnover, no follow-up 
therapy might be considered, whilst monitoring BMD 
and BTM 
APT = abaloparatide 
BMD = bone mineral density 
BPs = bisphosphonates 
BTM = bone turnover markers 
DMAB = denosumab 
HRT = hormone replacement therapy 
RMAB = romosozumab 
SERM = selective estrogen receptor modulator 
TPT = teriparatide  
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Table 1.  
 
Reference 
n = 
patients1 
n= in-
complete 
AFF2 
fracture 
line 
visible 
n= 
complete 
AFF2 
Sex 
Mean 
age 
Background3 Antiresorptives4 Condition 
Mean duration 
treatment in 
years (range)5 
Al Azzani, 2015 1 1 yes 0 M 54 Caucasian alendronate (5), ibandronate (5) cystic fibrosis 10 
Carvalho, 2011   
1 0 - 1 F 77 Caucasian alendronate 
postmenopausal 
osteoporosis 
4 
Cerveró, 2015   
1 1 yes 1 F 71 (Spain) alendronate 
postmenopausal 
osteoporosis 
5 
Chiu, 2013 
1 2 yes 0 F 63 (Taiwan) alendronate 
postmenopausal 
osteoporosis 
7 
Chew, 2013 1 1 yes 0 F 70 (Malaysia) alendronate back pain 6 
Etxebarria-
Foronda, 2015 
1 0 - 1 M 21 (Spain) 
pamidronate iv (3), alendronate 
(5) 
osteogenesis 
imperfecta 
8 
Fukuda, 2014   
1 1 yes 1 F 74 (Japan) alendronate 
postmenopausal 
osteoporosis 
6 
Giannotti, 2013   1 1 no 1 F 65 Caucasian  "bisphosphonates" NS 6 
Gomberg, 2011   
1 2 no (2) 0 F 63 Caucasian  alendronate 
glucocorticoid-induced 
osteoporosis 
13 
Holm, 20146   
1 0 - 1 NS NS (Norway) "bisphosphonates" 
osteogenesis 
imperfecta 
9 
Huang, 2012   1 1 yes 0 F 63 Asian  alendronate vertebral  fractures 3 
Iwata, 2014 
1 0 - 2 F 56 Asian  
incadronic iv 10mg two-weekly 
(3),  pamidronate iv 90 mg 
monthly (1), zoledronate iv 4mg 
monthly (5) 
metastatic bone 
disease 
9 
Jain, 2011   1 1 NS 1 F 75 (India) alendronate osteopenia 6 
Kaur, 2016    
1 1 no 0 F 70 Guyanese alendronate 
postmenopausal 
osteoporosis 
10 
Lampropoulou-
Adamidou, 2013   
1 0 - 1 F 84 Caucasian  alendronate (12), ibandronate (1) 
postmenopausal 
osteoporosis 
13 
Mastaglia, 2016   1 1 no 1 F 57 Caucasian  alendronate osteopenia 7 
Nguyen, 2017   
1 0 - 1 F 65 (Australia) alendronate 
postmenopausal 
osteoporosis 
11 
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Ramchand, 2016   
1 2 no (2) 0 F 82 (Australia) alendronate (6), risedronate (1) 
rib fracture 
osteoporosis 
7 
Reddy, 2012   
1 0 - 1 M 70 Asian  zoledronate iv 4mg monthly 
androgen deprivation 
therapy 
2 
Righetti, 2018   1 2 yes (1) 0 F 67 Armenian alendronate hypophosphatasia 10 
Román, 2015   
1 0 - 2 M 72 (Spain) alendronate 
glucocorticoid-induced 
osteoporosis 
11 
Schilcher, 2015 
1 0 - 1 F 84 (Sweden) "bisphosphonates" 
rheumatoid 
arthritis/Wegener 
granulomatosis 
16 
Selga, 2016   
1 0 - 2 F 62 (Spain) 
alendronate (10), risedronate (2), 
ibandronate (3), denosumab (2) 
osteoporosis 17 
Spyridonidis, 
2014   
1 1 yes 1 F 78 (Greece) alendronate osteoporosis 8 
Stathopoulos, 
2011  
1 0 - 1 F 76 Caucasian  zoledronate iv 4mg yearly osteoporosis 6 
Tan, 2017    
1 1 yes 0 M 63 (Singapore) alendronate (7), etidronate (2) 
osteogenesis 
imperfecta 
9 
Tarazona-
Santabalbina, 
2013   
1 1 yes 1 F 73 (Spain) alendronate osteoporosis 13 
Tsuchie, 2015   2 3 yes (3) 0 F 78 (Japan) alendronate osteoporosis 5 (4-6) 
Uppin, 2016   1 0 - 2 F 56 (India) alendronate rheumatoid arthritis 4 
Vaishya, 2013 1 2 yes (2) 0 F 63 (India) alendronate osteoporosis 3 
Visekruna, 2008   
2 0 - 3 F 69 Caucasian  alendronate, raloxifene 
steroid-dependent 
rheumatoid arthritis 
13 (10-16) 
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Table 2.  
 
Reference 
Total 
cohort, n 
Patients on 
TPT, n 
Controls 
without 
TPT, n 
Fracture 
type of TPT 
users* 
Female,  
n (%) 
Mean 
age 
(years) 
Country AR use 
Mean 
duration 
AR,  years 
(range) 
Main outcome 
Cheung, 
2013 
22 22 0 
Incomplete 
surgical = 3 
conservative 
= 19 
22 
(100%) 
66 Canada Yes (100%) 
12 (3.4-
28.7) 
Of 19 incomplete AFFs 
without surgery, 2 healed, 5 
were healing, 12 were 
stable after 2 years of TPT, 
but 4 patients developed 
new incomplete AFFs 
Lee, 2013 51 19 32 
Incomplete 
surgical = 12 
conservative 
= 7 
50 
(98%) 
70.4 South Korea Yes (77%) 4.5 
7 patients on TPT  and 19 
patients without TPT 
required surgery; Use of 
teriparatide did not 
significantly reduce the 
need for surgery (p = 0.210) 
Lee, 2017 44 14 30 
Complete  
n = 14 AFFs 
44 
(100%) 
70.1 South Korea Yes (100%) 5.1 
Time to healing was 4.9 
months in TPT-group,6.6 
months in non-TPT-group 
and 7.1 months in those 
continued on 
bisphosphonates 
Miyakoshi, 
2015  
34 
NS 
(21 AFFs) 
NS 
(24 AFFs) 
Incomplete 
surgical = 5 
AFFs 
conservative 
= 5 
Complete  
n=11 AFFs 
34 
(100%) 
78.5 Japan 
Alendronate or 
risedronate 
(100%) 
4.4 (1-
11.7) 
Time to healing was 
significantly shorter for all 
surgically treated AFF in 
TPT-group (5.4 vs. 8.6 
months) 
Petraszko, 
2016 
7 6 1 
Incomplete 
conservative 
= 8 AFFs 
 surgical = 1 
AFF 
7 
(100%) 
70.7 USA Yes (100%) 
10.6 (7-
15) 
Fracture line disappeared in 
2 of 6 AFFs with a visible 
line within one year of TPT 
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Saleh, 
2012 
10 9 1 
Incomplete 
conservative 
= 13 AFFs 
10 
(100%) 
66.8 USA 
Alendronate or 
risedronate 
(100%) 
10 (4-17) 
5 AFFs without line all 
healed, 7 of 8 AFFs with 
fracture line had surgery 
after 3 months of TPT 
Sato, 2017 12 6 6 
Incomplete 
conservative 
= 6 
12 
(100%) 
55.6 Japan 
Alendronate 
(100%) 
5.9 (3.1-
9.3) 
All AFFs on continued 
bisphosphonates 
deteriorated; 1 AFF 
progressed to complete 
fracture after 8 months of 
TPT 
Takakubo, 
2017 
8 4 4 
NS 
surgical = 5 
AFFs 
8 
(100%) 
54.9 Japan 
Alendronate, 
risedronate, 
minodronate 
(100%) 
4.3 (2-10) 
Time to healing was 11.5 
months in 5 AFFs on TPT 
and 13.3 months in 6 AFFs 
without TPT, but 1 AFF was 
not healed after 1 year and 
lost to followup in the TPT-
group 
Yeh, 2017 13 NS (8 AFFs) NS (8 AFFs) 
Complete  
n = 8 AFFs 
13 
(100%) 
70.2 Taiwan 
Alendronate 
(100%) 
4.0 (2.5-6) 
Time to healing was 4.4 
months in the TPT-group 
versus 6.2 months in the 
non-TPT group 
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Table 3.  
Reference 
Total 
cohort, n 
Patients on 
TPT, n 
Controls 
without 
TPT, n 
Fracture 
type of TPT 
users* 
Female, 
n (%) 
Mean 
age, 
(years) 
Country AR use 
Mean 
duration 
AR,  years 
(range) 
Main outcome 
Chiang, 
2013 
14 5 9 
Incomplete 
n = 4 
Complete 
n = 1 
13 
(93%) 
76 Australia 
Alendronate, 
risedronate, 
pamidronate, 
zoledronate 
(100%) 
7 (4-10) 
TPT users: 2  healed, 3 
had partial healing 
Controls: 3 prophylactic 
surgery, 1 contralateral 
AFF, 6 with non-union 
Greenspan, 
2018 
13 
           13 
- 7 immediate 
post-surgery 
- 6 on 
teriparatide 6 
months 
postoperatively 
0 
Incomplete 
surgical = 1 
Complete 
n = 12 
13 
(100%) 
74 USA 
Risedronate, 
ibandronate, 
alendronate 
(100%) 
NS 
Higher bone healing 
scores in 
immediate TPT group, 
but not statistically 
significant 
Watts, 
2017 
14 14 0 
Complete 
n = 9 
Incomplete 
surgical 
 = 1 
conservative 
= 4 
14 
(100%) 
68 USA 
Alendronate, 
ibandronate, 
zoledronate, 
risedronate 
(100%) 
8.8 (3-
14.5) 
Complete AFFs: 4 healed, 
5 partial healing, 1 
nonunion. 
Incomplete AFF: 4 partial 
healing, 3 unchanged. 
2 contralateral complete 
AFFs 
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Table 4.  
 
Fracture healing and teriparatide 
use 
n=140 patients 
Incomplete AFF 
(conservative) 
Incomplete AFF 
(surgical) 
Complete AFF 
TPT TPT TPT No TPT 
 Number of AFFs (total 165) 30 10 58 67 
Healing ≤ 6 months of TPT 13 (43%) 9 (90%) 44 (76%) 34 (51%) 
Healing 6 < or ≥ 12 months of TPT  4 (13%) 1 (10%) 9 (16%) 29 (43%) 
No union achieved at 12 months  9 (30%) - 5 (9%) 4 (6%) 
Progression to complete AFF  4 (13%) NA NA NA 
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Table 5.  
 
 Osteoporosis (n=11) Bone metastases (n=11) Overall (n=22) 
No. of AFFs 15 16 31 
Mean age (min-max) 70.7 (59-81) 54.7 (50-86) 62.7 (50-86) 
Female (%) 10 (91%) 10 (91%) 20 (91%) 
Complete AFFs (%) 11 (73%) 6 (38%) 17 (77%) 
Incomplete AFFs (%) 4 (27%) 10 (62%) 14 (64%) 
BP use 7 (64%) 7 (64%) 14 (64%) 
BP-naive 4 (36%) 4 (36%) 8 (36%) 
Mean duration of BP,  
years (range) 
9.0 (5 weeks-15 years) 7.8 (6-11.3) 8.4 (5 weeks – 15 years) 
Number of denosumab 
doses, mean (range) 
3.2 of 60mg half-yearly 
(1-14) 
30 of 120mg monthly 
(18-48) 
- 
Accumulative dose,  
mg/year 
120 1440 - 
Number of denosumab 
doses in BP-naïve 
patients, mean (range) 
5.8 (1-14) 29 (21-42) - 
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